Related references
Note: Only part of the references are listed.In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
Tami Pilot-Matias et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Changes in hepatitis C virus genotype distribution in Japan
H. Toyoda et al.
EPIDEMIOLOGY AND INFECTION (2014)
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2014)
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Pietro Andreone et al.
GASTROENTEROLOGY (2014)
Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource
Donald B. Smith et al.
HEPATOLOGY (2014)
Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
David A. DeGoey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
Kelly A. Wong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A
David A. DeGoey et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Khayriyyah Mohd Hanafiah et al.
HEPATOLOGY (2013)
SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
I. Jacobson et al.
JOURNAL OF HEPATOLOGY (2013)
THE CLIF-CONSORTIUM SCORE PREDICTS MORTALITY MORE ACCURATELY THAN THE MELD AND MELD-SODIUM SCORES IN PATIENTS HOSPITALIZED WITH DECOMPENSATED CIRRHOSIS WITH AND WITHOUT ACUTE-ON-CHRONIC-LIVER FAILURE (ACLF)
M. Pavesi et al.
JOURNAL OF HEPATOLOGY (2013)
TREATMENT-EMERGENT VARIANTS FOLLOWING 3 DAYS OF MONOTHERAPY WITH IDX719, A POTENT, PAN-GENOTYPIC NS5A INHIBITOR, IN SUBJECTS INFECTED WITH HCV GENOTYPES 1-4
J. F. McCarville et al.
JOURNAL OF HEPATOLOGY (2013)
NS5A inhibitors in the treatment of hepatitis C
Jean-Michel Pawlotsky
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
Jeremie Guedj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The science of direct-acting antiviral and host-targeted agent therapy
Jean-Michel Pawlotsky
ANTIVIRAL THERAPY (2012)
Novel Hepatitis C virus replicon inhibitors: Synthesis and structure-activity relationships of fused pyrimidine derivatives
A. Chris Krueger et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
I. M. Jacobson et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Evolving epidemiology of hepatitis C virus
D. Lavanchy
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Recombinant HCV Variants With NS5A From Genotypes 1-7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α
Troels K. H. Scheel et al.
GASTROENTEROLOGY (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro
Sam Hopkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles
Mair Hughes et al.
JOURNAL OF GENERAL VIROLOGY (2009)
Regulation of hepatitis C virion production via phosphorylation of the NS5A protein
Timothy L. Tellinghuisen et al.
PLOS PATHOGENS (2008)
euHCVdb: the European hepatitis C virus database
Christophe Combet et al.
NUCLEIC ACIDS RESEARCH (2007)
Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera
Rakesh L. Tripathi et al.
ANTIVIRAL RESEARCH (2007)
Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein
LY Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro
HM Mo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Hepatitis C virus NS5A: tales of a promiscuous protein
A Macdonald et al.
JOURNAL OF GENERAL VIROLOGY (2004)
Genetic diversity and evolution of hepatitis C virus - 15 years on
P Simmonds
JOURNAL OF GENERAL VIROLOGY (2004)
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon
T Kato et al.
GASTROENTEROLOGY (2003)
Clinical significance of hepatitis C virus genotypes
NN Zein
CLINICAL MICROBIOLOGY REVIEWS (2000)
Share Paper
